Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial

Background: Cytomegalovirus (CMV), a common post‐transplant infection, is associated with increased healthcare resource utilization. In the Phase 3 SOLSTICE trial, maribavir was superior to investigator‐assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, and cidofovir) for CMV viremia clearance at Week 8 in transplant recipients with confirmed refractory CMV infection with/without resistance. This exploratory analysis evaluated hospital admissions of patients during the SOLSTICE trial. Methods: Patients were randomized to maribavir (400 mg twice daily) or IAT for an 8‐week treatment phase with a 12‐week follow‐up. After ≥3 weeks of treatment, patients on IAT who met pre‐specified criteria could enter a maribavir rescue arm (8‐week maribavir treatment, 12‐week follow‐up). Adjusted hospitalization rates and length of hospital stay (LOS) were estimated using negative binomial models adjusting for the time in the relevant study phase. Subgroup analysis for the maribavir rescue arm was conducted. Results: Overall, 352 patients were randomized (maribavir: 235; IAT: 117); 22 entered the maribavir rescue arm. After adjusting for treatment exposure, patients on maribavir had a 34.8% reduction in hospitalization rate and 53.8% reduced LOS (days/person/year) versus IAT during the treatment phase. No significant differences between treatments were observed during the follow‐up phase, although in both arms, hospitalization rates were lower than in the treatment phase. In the maribavir rescue arm, hospitalizations were 60.6% lower on/after maribavir rescue versus pre‐rescue treatment (p = 0.008). Conclusion: In patients requiring post‐transplant CMV treatment, hospitalization rate and LOS were lower for maribavir than IAT, and hospitalization rates were lower on/after maribavir rescue than pre‐rescue. Reducing hospitalizations can alleviate the burden on patients and healthcare systems. [ABSTRACT FROM AUTHOR]